Parathyroid hormone analogs are the only widely approved drugs that build new bone rather than simply slowing its breakdown, making them a distinct and powerful class of osteoporosis treatment. Teriparatide, the first to market, and abaloparatide, a newer synthetic cousin, both work by mimicking the bone-building effects of the body’s own parathyroid hormone when given as brief daily doses. The biology behind them is genuinely counterintuitive: parathyroid hormone can either strengthen or weaken bone depending entirely on how it is delivered, and that paradox shapes everything about how these drugs are prescribed, how long you can take them, and what has to come next.
Why a Hormone That Breaks Down Bone Can Also Build It
Parathyroid hormone, or PTH, has a day job that has nothing to do with osteoporosis treatment. Your parathyroid glands release it continuously to keep blood calcium levels stable, and one of the ways it does that is by pulling calcium out of bone. People with hyperparathyroidism, whose glands overproduce the hormone around the clock, tend to lose bone mass over time. So the idea that injecting a version of this same hormone could treat bone loss sounds backwards.
The key is timing. When PTH is present continuously, it activates genes and pathways that favor bone resorption. But when it arrives in a short pulse and then clears completely before the next dose, it preferentially stimulates bone-forming cells called osteoblasts. The same hormone, delivered differently, flips the balance from catabolic to anabolic.
1PubMed Central. Parathyroid hormone: anabolic and catabolic actions on the skeleton This is why PTH analogs are given as once-daily injections that produce a quick spike in blood levels followed by rapid clearance, rather than as a slow-release formulation. In older animals, the hormone naturally tends toward net bone loss as part of its calcium-regulation role; the therapeutic trick is overriding that default with intermittent dosing.2PubMed. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone
Teriparatide and Abaloparatide
Teriparatide is a synthetic copy of the first 34 amino acids of human parathyroid hormone. It was approved in the early 2000s and remains the most studied bone-building drug for osteoporosis. Full-length PTH (all 84 amino acids) has also been tested and shown to increase bone mineral density and reduce fractures in postmenopausal women, though it never gained the same clinical foothold.3PubMed Central. Parathyroid hormone (1-84) and teriparatide in the treatment of postmenopausal osteoporosis Teriparatide’s shorter fragment turned out to be easier to manufacture and dose, and it became the workhorse of anabolic osteoporosis therapy.
Abaloparatide arrived later as a synthetic analog of parathyroid hormone-related protein, a molecule related to PTH but not identical. It binds the same receptor on bone cells but with a twist: it has a stronger preference for a particular receptor shape (called the RG conformation) that produces shorter-lived signaling bursts inside the cell.4Endocrinology. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling In practical terms, this more transient signal may mean abaloparatide stimulates bone formation with slightly less accompanying bone resorption and slightly less tendency to raise blood calcium. Both drugs are given as daily subcutaneous injections, and both have a lifetime treatment cap of 24 months.
How Well They Reduce Fractures
The fracture data for teriparatide are strong, particularly for vertebral fractures. In the original Fracture Prevention Trial, postmenopausal women on placebo who had one, two, or three or more existing vertebral fractures developed new vertebral fractures at rates of about 7%, 16%, and 23% respectively over a median of 21 months. Among women treated with teriparatide, that dose-response pattern essentially disappeared: the drug blocked the rising fracture risk that normally comes with having more prior fractures.5PubMed. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures
The VERO trial provided the first head-to-head fracture comparison between teriparatide and a standard antiresorptive drug (risedronate, a bisphosphonate) in women with severe postmenopausal osteoporosis. After two years, new vertebral fractures occurred in about 5% of the teriparatide group compared with 12% in the risedronate group, and clinical fractures overall were roughly halved.6The Lancet. Effect of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a randomised, double-blind, double-dummy trial The difference in fracture rates showed up within the first seven months, suggesting that teriparatide’s bone-building action translates to mechanical protection relatively quickly.7PubMed Central. Efficacy of teriparatide compared with risedronate on FRAX-defined major osteoporotic fractures: results of the VERO clinical trial
Why You Cannot Just Stop
One of the most important and underappreciated aspects of PTH analog therapy is what happens when it ends. Unlike bisphosphonates, which linger in bone for years after you stop taking them, teriparatide and abaloparatide clear the body quickly. When treatment stops, the bone density gains begin reversing within months unless another drug steps in.
The DATA-Follow-up study quantified this starkly. Among women who had received teriparatide and denosumab and then stopped without follow-up treatment, bone mineral density at the spine dropped by about 10% and at the hip by roughly 4% to 5%. Women who transitioned promptly to an antiresorptive drug essentially held onto their gains, with density changes hovering around 1% or less at all sites.8PubMed. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up) The EUROFORS trial showed a similar pattern: patients who received raloxifene after finishing teriparatide maintained their spine density gains (about 8% above baseline), while those who got no follow-up treatment saw their gains erode.9Journal of Bone and Mineral Research. Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
This means PTH analogs are never a standalone treatment. They are always the first act in a two-act strategy: build bone first, then lock it in with a bisphosphonate or denosumab. Doctors sometimes call this “sequential therapy,” and getting the transition right matters as much as the initial anabolic phase. Delays of even a few months can cost patients a meaningful chunk of the density they worked to gain.
Combining Teriparatide with Other Drugs
If sequential therapy is effective, the natural question is whether using teriparatide and an antiresorptive simultaneously does even better. The DATA study tested exactly this, randomizing postmenopausal women to teriparatide alone, denosumab alone, or both together. At 12 months, the combination group saw spine density rise by about 9%, compared with roughly 6% for teriparatide alone and about 5.5% for denosumab alone. At the hip, the combination advantage was even more pronounced: nearly 5% for the combo versus under 1% for teriparatide alone.10PubMed Central. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
By the end of two years, the gap widened further. The combination group gained about 13% at the spine, compared with roughly 9.5% for teriparatide and about 8% for denosumab. At the femoral neck, combination therapy produced gains of nearly 7%, compared with under 3% for teriparatide alone and about 4% for denosumab.11The Journal of Clinical Endocrinology & Metabolism. Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial These are among the largest bone density increases reported with any approved osteoporosis regimen. The combination approach is not yet standard practice everywhere, but for patients at very high fracture risk, it represents the most aggressive bone-building strategy available.
What Teriparatide Actually Does to Bone Structure
Bone mineral density, the number you see on a DEXA scan, captures part of the story but not all of it. PTH analogs reshape the internal architecture of bone in ways that density measurements alone can miss, and not all of those changes are straightforwardly positive.
In the spine and other sites rich in trabecular (spongy) bone, teriparatide thickens the mesh of bony struts and adds new connections between them, which is the main reason vertebral fracture risk drops so sharply. But at cortical-heavy sites like the wrist and the outer shell of the shinbone, the picture is more complicated. High-resolution imaging studies show that teriparatide increases cortical porosity, sometimes substantially. In one study, cortical porosity at the radius rose by about 21% over the treatment period, and cortical density at both the radius and tibia declined modestly.12PubMed Central. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study Another study confirmed these cortical changes, finding decreased cortical density at the distal radius and tibia after 18 months of treatment.13PubMed. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
This is one of the more nuanced aspects of PTH analog therapy. The cortical porosity increase is thought to be a temporary remodeling effect: teriparatide wakes up dormant tunnels within cortical bone as part of the broader acceleration of bone turnover. When an antiresorptive drug is given afterward, those pores tend to fill back in and cortical density recovers. The combination of teriparatide with denosumab avoided the cortical porosity increase entirely, which is another argument for the combination approach in patients whose cortical bone is already thin.
The Osteosarcoma Scare and Its Resolution
For nearly two decades, teriparatide’s prescribing label carried a boxed warning about a potential risk of osteosarcoma, the most serious type of bone cancer. The warning originated from rat studies in which animals given high doses of teriparatide for most of their lifespan developed bone tumors. This finding was enough to trigger regulatory caution, and it limited how many clinicians felt comfortable prescribing the drug and for how long.
The human evidence told a very different story. Multiple postmarketing studies comparing osteosarcoma rates in people who had used teriparatide against unexposed groups and against the expected population background rate found no increase in risk.14PubMed Central. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates A study that linked commercial pharmacy records to state cancer registries confirmed that osteosarcoma incidence among teriparatide users was within the expected range for the general population. Based on this accumulated real-world evidence, the boxed warning was removed in 2020.15PubMed. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes The removal expanded treatment options for patients whose physicians had previously been reluctant to prescribe the drug.
Common Side Effects
The side effects of teriparatide are generally mild and predictable given that you are injecting a calcium-regulating hormone. A temporary bump in blood calcium is the most common biochemical change, typically peaking four to six hours after injection and returning to normal before the next dose. Urinary calcium also rises, by about 30 mg per day on average.16ScienceDirect. Teriparatide: A review For most people this is clinically insignificant, but it can matter for patients with a history of kidney stones.
Injection-site reactions, dizziness, nausea, and leg cramps are reported by some users but rarely lead to discontinuation. The calcium fluctuations deserve the most monitoring attention, particularly in people taking calcium or vitamin D supplements alongside treatment, since the combination can tip blood calcium higher than expected.
Glucocorticoid-Induced Osteoporosis
Long-term use of corticosteroids like prednisone is one of the most common causes of secondary osteoporosis, and it produces a particularly aggressive form of bone loss that standard antiresorptive drugs struggle to counter. Teriparatide has carved out a strong niche here. In a head-to-head trial against alendronate (a bisphosphonate), teriparatide increased lumbar spine density by about 7.2% compared with 3.4% for alendronate over the study period, with the gap reaching statistical significance by six months. More striking was the fracture difference: new vertebral fractures occurred in 0.6% of the teriparatide group versus 6.1% of the alendronate group.17PubMed. Teriparatide or alendronate in glucocorticoid-induced osteoporosis
A separate trial in men with glucocorticoid-induced osteoporosis found that 18 months of teriparatide produced substantially larger improvements in spinal trabecular density, bone microstructure, and estimated vertebral strength compared with risedronate. Teriparatide increased trabecular density by about 16% versus 4% for risedronate, and estimated vertebral strength gains ranged from about 26% to 34% for teriparatide compared with roughly 4% to 7% for risedronate.18Journal of Bone and Mineral Research. Comparative effects of teriparatide and risedronate in glucocorticoid‐induced osteoporosis in men: 18‐month results of the EuroGIOPs trial The advantage makes biological sense: corticosteroids suppress osteoblast function, which is exactly what teriparatide counteracts. Antiresorptive drugs slow breakdown but cannot rebuild what corticosteroids have already destroyed.
Treatment Duration and the Two-Year Ceiling
Depending on the country, teriparatide is approved for a lifetime maximum of 24 months of treatment.19PubMed Central. Teriparatide for osteoporosis: importance of the full course This cap originally stemmed from the rat osteosarcoma data and was retained even after the boxed warning was removed, partly because clinical trial data beyond two years remain limited and partly because the anabolic window appears to plateau. After about 18 to 24 months, the gap between bone formation and bone resorption markers narrows, and the net anabolic advantage diminishes.
Adherence through the full course matters. Patients who stop early forgo both the continued density gains of the second year and the optimal starting point for the antiresorptive consolidation phase that follows. There has been interest in whether retreatment (a second course years later) could provide another round of bone building, but the evidence on this remains thin and no regulatory body has formally endorsed it. For now, the two-year window is treated as a one-time investment.
Monitoring Treatment Response
Unlike antiresorptive drugs, where success is judged mainly by density scans every one to two years, PTH analog therapy has a useful early biomarker. PINP, a peptide released when new collagen is laid down in bone, rises within the first month of teriparatide treatment. In research settings, the one-month change in PINP correlated strongly with the 12-month change in lumbar spine density.20PubMed. PINP as an aid for monitoring patients treated with teriparatide Both PINP and a related marker (PICP) have been identified as among the best early predictors of density response to teriparatide.21Journal of Bone and Mineral Research. Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis
In practice, a doctor might check PINP at baseline and again after one to three months. A robust increase confirms that the drug is working at a cellular level and the patient is injecting correctly. A flat or minimal rise could signal poor adherence, improper injection technique, or an unusually blunted biological response, prompting a conversation before waiting a full year for a DEXA scan to reveal the problem.
Kidney Disease Complicates the Picture
Teriparatide is cleared by the kidneys, and its calcium-raising effects become more unpredictable as kidney function declines. In patients with severe chronic kidney disease, the drug should be prescribed with extra caution.22PubMed Central. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study The risk of hypercalcemia is heightened, partly because these patients often have disordered calcium-phosphate metabolism and abnormal parathyroid function to begin with. One review noted hypercalcemia rates as high as about 22% in this population, far above what is seen in patients with normal kidneys.23PubMed. Application of teriparatide in CKD-related osteoporosis: efficacy and safety considerations
This does not mean PTH analogs are off-limits for people with kidney disease, but it does mean closer monitoring of calcium levels and a more careful risk-benefit discussion. For patients on dialysis or with very advanced kidney failure, the calculus changes substantially, and alternative approaches to bone health often take priority.
Healing Atypical Femur Fractures
Atypical femoral fractures are a rare but serious complication of long-term bisphosphonate use. These stress fractures occur along the shaft of the thighbone, in a location and pattern distinct from the typical hip fractures that bisphosphonates are designed to prevent. They heal slowly and sometimes fail to heal at all, likely because the bone remodeling machinery has been suppressed for too long by the antiresorptive drug.
Teriparatide has emerged as a treatment strategy for these difficult fractures. A meta-analysis of studies comparing atypical femur fracture outcomes with and without teriparatide found that patients who did not receive the drug had significantly higher rates of both delayed union and nonunion. On average, teriparatide shortened fracture healing time by about 1.7 months.24PubMed. The effect of teriparatide on fracture healing after atypical femoral fracture: A systematic review and meta-analysis This represents one of the more compelling off-label uses of the drug: using an anabolic agent to restart bone repair that an antiresorptive drug has stalled.
Getting Past the Daily Injection
One of the biggest practical barriers to PTH analog therapy is that it requires a daily self-administered subcutaneous injection. For some patients, especially older adults with limited dexterity or needle anxiety, this is a dealbreaker. Researchers have been working on alternatives, particularly microneedle patches that deliver the drug through the skin without a traditional needle.
A transdermal patch system designed for rapid pulse delivery of teriparatide has been tested in clinical pharmacokinetic studies, aiming to replicate the brief peak-and-clear blood level pattern that makes the drug anabolic rather than catabolic.25PubMed. Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis More recently, dissolving microneedle patches loaded with teriparatide acetate for once-weekly dosing have been developed in lab settings.26PubMed Central. Development of Clinical Weekly-Dose Teriparatide Acetate Encapsulated Dissolving Microneedle Patch for Efficient Treatment of Osteoporosis The appeal of a weekly patch over a daily injection is obvious for adherence: fewer doses, no visible needle, and potentially something a patient can apply without help. These systems are not yet commercially available, but they represent the likely direction of future PTH analog delivery.
The transdermal challenge is not trivial. Teriparatide is a peptide, and peptides generally do not cross skin well on their own. The microneedle approach works by creating tiny channels in the outer skin layer through which the drug can reach the bloodstream. The pharmacokinetic profile has to be right, too. If the patch releases the drug too slowly, you lose the intermittent pulse that makes PTH anabolic and risk tipping toward the catabolic side. Getting both the delivery efficiency and the timing right has been the central engineering problem, and early clinical data on postmenopausal women showed that the transdermal approach could increase bone density.27The Journal of Clinical Endocrinology & Metabolism. Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women